In last trading session, Myriad Genetics, Inc. (NASDAQ:MYGN) saw 1,627,832 shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $11 trading at -$0.1 or -0.99% at ring of the bell on the day assigns it a market valuation of $820.1 Million. That closing price of MYGN’s stock is at a discount of -340% from its 52-week high price of $48.4 and is indicating a premium of 16% from its 52-week low price of $9.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.66 Million shares which gives us an average trading volume of 1.19 Million if we extend that period to 3-months.

For Myriad Genetics, Inc. (MYGN), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3. Splitting up the data highlights that, out of 9 analysts covering the stock, 1 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 1 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.44 in the current quarter.

Myriad Genetics, Inc. (NASDAQ:MYGN) trade information

In the face of being in the red today for losing -0.99%, in the last five days MYGN remained trading in the green while hitting it’s week-highest on Friday, Jun 19 when the stock touched $13.12- price level, adding 16.16% to its value on the day. Myriad Genetics, Inc.’s shares saw a change of -59.6% in year-to-date performance and have moved -14.86% in past 5-day. Myriad Genetics, Inc. (NASDAQ:MYGN) showed a performance of -25.32% in past 30-days. Number of shares sold short was 8.91 Million shares which calculate 7.49 days to cover the short interests.

Myriad Genetics, Inc. (MYGN) estimates and forecasts

Statistics highlight that Myriad Genetics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -59.81% of value to its shares in past 6 months, showing an annual growth rate of -107.78% while that of industry is 9.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -207.3% in the current quarter and calculating -162.5% decline in the next quarter. This year revenue growth is estimated to drop -24.4% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $91.74 Million for the same. And 5 analysts are in estimates of company making revenue of $144.59 Million in the next quarter that will end in September 01, 2020. Company posted $215.4 Million and $186.3 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -57.4% while estimating it to be -22.4% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -51.5% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -95.7% while estimates for its earnings growth in next 5 years are of 8.1%

Myriad Genetics, Inc. (NASDAQ:MYGN)’s Major holders

Insiders are in possession of 1.76% of company’s total shares while institution are holding 107.18% percent of that, with stock having share float percentage of 109.1%. Investors also watch the number of corporate investors in a company very closely, which is 319 institutions for Myriad Genetics, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at MYGN for having 12.46 Million shares of worth $178.28 Million. And as of March 30, 2020, it was holding 16.71% of the company’s outstanding shares.

The second largest institutional holder is Baillie Gifford and Company, which was holding about 8.97 Million shares on March 30, 2020. The number of shares represents firm’s hold over 12.03% of outstanding shares, having a total worth of $128.36 Million.

On the other hand, iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 4521987 shares of worth $64.71 Million or 6.07% of the total outstanding shares. The later fund manager was in possession of 2.09 Million shares on March 30, 2020, making its stake of worth around $29.84 Million in the company or a holder of 2.8% of company’s stock.